Pulmonary hypertension in China: Pulmonary vascular disease: The global perspective

Zhenguo Zhai, Jun Wang, Lan Zhao, Jason X.J. Yuan, Chen Wang

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Significant progress has been made in understanding the pathogenesis of pulmonary hypertension (PH) and developing therapeutic approaches for PH in recent years. Most of the currently available data regarding the prevalence, diagnosis, treatment, and prognosis of PH are from American and European populations. Whether these data are also valid in the Chinese population is still controversial. China has a relatively large population of patients with PH for clinical and basic research. However, many medical centers and hospitals in China have limited experience with PH diagnosis and treatment. Given the potential higher prevalence of PH in China than in the United States and European countries, it is critical to develop suitable, effective, and novel therapeutic approaches for Chinese patients. Measures for the detection and prevention of PH need to be put in place urgently for the management of PH in China.

Original languageEnglish (US)
Pages (from-to)69S-77S
Issue number6 SUPPL.
StatePublished - Jun 1 2010
Externally publishedYes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Pulmonary hypertension in China: Pulmonary vascular disease: The global perspective'. Together they form a unique fingerprint.

Cite this